Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

NCT01749137 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight

Interventions

DRUG: Setmelanotide
DRUG: Placebo

Sponsor

Rhythm Pharmaceuticals, Inc.